Efficacy and safety of rTMS for global symptom severity, negative symptoms, and auditory hallucinations in treatment-resistant schizophrenia: a systematic review and meta-analysis.

Authors

Mohammed A Alhassan, Mohammed A Alarabi, Waled M Albalawi, Thenuwara Arachchige Omila Kasun Meetiyagoda, Anum Nisar, John Robert M Torres

Published in

Frontiers in psychiatry. Volume 17. Pages 1783758. Epub Jul 24, 2026.

Abstract

Treatment-resistant schizophrenia (TRS) affects up to one-third of individuals with schizophrenia and remains a major clinical challenge despite optimized pharmacotherapy. Repetitive transcranial magnetic stimulation (rTMS) has been proposed as a neuro-modulatory intervention for refractory symptoms, yet evidence specific to TRS remains limited and inconsistent.
To evaluate the efficacy and safety of rTMS for reducing global symptom severity, negative symptoms, and auditory hallucinations in adults with treatment-resistant schizophrenia, and to examine the influence of stimulation parameters on treatment outcomes.
A systematic review and meta-analysis was conducted following PRISMA guidelines and registered with PROSPERO (CRD420251143558). Eight electronic databases were searched up to 10^th September 2025. Randomized controlled trials including adults with TRS and comparing rTMS with sham stimulation were eligible. Standardized mean differences (Hedges' g) were pooled using REML-based random-effects models. Heterogeneity and subgroup effects were examined, and publication bias was explored through visual inspection of funnel plots.
Across included trials, rTMS was not associated with statistically significant improvements in overall symptom severity measured by PANSS (SMD 0.14, 95% CI -0.26 to 0.54), negative symptoms (SMD 0.37, 95% CI -0.12 to 0.86), or auditory hallucinations measured by AHRS (SMD -0.03, 95% CI -0.26 to 0.20), based on post-treatment outcome scores. Substantial heterogeneity was observed for PANSS and negative symptoms, while heterogeneity for AHRS was low. Subgroup findings were exploratory and should be interpreted cautiously.
Current evidence does not support a consistent therapeutic benefit of rTMS over sham stimulation for symptom reduction in treatment-resistant schizophrenia. While some subgroup analyses suggested variability in effect estimates across stimulation protocols, these findings were exploratory and should be interpreted with caution. Further large-scale, well-designed trials are needed to clarify the role of rTMS in this population.
https://www.crd.york.ac.uk/PROSPERO/view/CRD420251143558, identifier CRD420251143558.

PMID:
42568920
Bibliographic data and abstract were imported from PubMed on 08 Aug 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.